June 6, 2017August 24, 2022
University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis
News
University of Michigan researchers have shed more light on the genetic landscape behind the intricate mechanisms of psoriasis. The 16 ... Read more
June 1, 2017
OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany
News
One World Cannabis Pharmaceutical Research (OWCP) and mediq Innovation Experts have partnered to introduce OWCP’s cannabinoid-based topical psoriasis cream in Germany. ... Read more
May 30, 2017May 30, 2017
FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis
News
The U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) for Sun Pharmaceutical’s lead investigational drug tildrakizumab ... Read more
May 25, 2017May 25, 2017
Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis
News
Janssen announced two new Phase 3 clinical trials for psoriasis for its investigational drug guselkumab. The company intends to explore ... Read more
May 23, 2017
Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests
News
Patients taking Remicade (infliximab) can safely switch to treatment with biosimilar CT-P13, sold as Pfizer’s Inflectra and Celltrion Healthcare’s Remsima, according to ... Read more
May 16, 2017May 16, 2017
Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows
News
Compounds extracted from the cannabis plant (cannabinoids) have therapeutic proprieties that could be used to treat several skin conditions, including psoriasis, ... Read more
May 11, 2017
Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target
News
An already started Phase 2b clinical trial of Prurisol as a treatment for moderate-to-severe chronic plaque psoriasis has recruited more than 70 ... Read more
May 9, 2017
Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease
News
Pfizer’s rheumatoid arthritis drug Xeljanz (tofacitinib) was effective against nail psoriasis in patients with plaque disease, according to data from ... Read more
May 4, 2017May 4, 2017
FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients
News
The U.S. Food and Drug Administration (FDA) will review Pfizer’s medication Xeljanz (tofacitinib citrate) 5 mg twice daily, to treat adults with ... Read more
May 2, 2017
Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales
News
The U.K.’s National Institute for Health and Care Excellence (NICE) has approved the use of Cimzia (certolizumab pegol) and Cosentyx (secukinumab), ... Read more
April 27, 2017April 27, 2017
Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month
News
Siliq (brodalumab) injection, recently approved to treat adults with severe plaque psoriasis, will be available in the U.S. at a ... Read more
April 20, 2017April 20, 2017
XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata
News
XTRAC targeted-light therapy safely treats skin lesions in psoriasis patients without the serious side effects linked to Humira and other conventional psoriasis drugs, ... Read more

August 18, 2016

Review Highlights Links Between Psoriasis and Diet, Nutrition, Obesity

News

Growing evidence suggests that nutrition plays a major role in the development of psoriasis, with the likelihood that body weight and diet will exacerbate or trigger the disease. In a recent ... Read more

August 17, 2016August 17, 2016

Survey of Psoriasis Patients Highlights Disease’s Emotional Toll, Treatment Challenges

News

A new survey by Health Union, titled “Psoriasis in America 2016,” has revealed that although psoriasis patients agree that a variety of treatment plans are available, they find it difficult to find one that ... Read more

August 15, 2016August 15, 2016

Biologics May Be Effective Option for Children with Generalized Pustular Psoriasis

News

Biologics may be a promising treatment for pediatric patients with generalized pustular psoriasis (GPP) who are not responding to traditional therapies, but clinical trials better establishing their safety and efficacy ... Read more

August 11, 2016August 11, 2016

Coherus Reports Positive Initial Data in Ongoing Study of Humira Biosimilar to Treat Plaque Psoriasis

News

Coherus BioSciences recently reported that its ongoing Phase 3 pharmacokinetic and bioequivalence study comparing biosimilar CHS-1420, a candidate treatment for plaque psoriasis, to Humira (adalimumab) successfully met its 12-week endpoints. Specifically, the study demonstrated similarity ... Read more

August 10, 2016August 10, 2016

Potential Oral Treatment for Psoriasis Shows Efficacy in Phase 2/3 Study

News

Can-Fite BioPharma has announced the completion of its Phase 2/3 clinical trial evaluating Piclidenoson (CF101) as an oral treatment for moderate to severe psoriasis. The results show that Piclidenoson is both ... Read more

August 9, 2016August 9, 2016

Psoriasis Patients at High Risk of Chronic Pancreatitis, Study Finds

News

People with psoriasis, especially those with severe psoriasis, are at high risk of chronic pancreatitis (CP), researchers reported in the study, “The Risk of Chronic Pancreatitis in Patients with Psoriasis: A ... Read more

August 8, 2016August 8, 2016

Psoriasis Linked to Social Anxiety and Depression in Study

News

Psoriasis is linked to depression, poor sleep quality, and anxiety interacting with and being around others, researchers from University Hospital Policlinico-Vittorio Emanuele in Italy reported. The findings were recently published in the International Journal ... Read more

August 5, 2016August 5, 2016

Results of Pivotal Studies Show Taltz Treatment Helped Plaque Psoriasis Patients Be More Productive

News

Results from three, Phase 3 clinical trials showed that patients with moderate-to-severe psoriasis who were treated with Taltz (ixekizumab) reported significant improvements in work productivity over those treated with placebo. The randomized, double-blind, studies were led ... Read more

August 4, 2016August 4, 2016

Sandoz Reports Biosimilar for Enbrel Effectively Treated Plaque Psoriasis in Phase 3 Study

News

Sandoz, a division of Novartis, reported that its clinical trial comparing the efficacy and the safety of GP2015, its biosimilar candidate to Enbrel (etanercept), met its primary endpoint — effectiveness ... Read more

August 3, 2016August 3, 2016

Infliximab Biosimilar as Effective as Remicade in Treating Psoriasis, Study Finds

News

Psoriasis patients using the anti-inflammatory drug Remicade (infliximab) who switched to an infliximab biosimilar had no significant change in clinical response or reported adverse events, researches investigating the medication changed reported. The article, “The ... Read more

University of Michigan Researchers Identify 16 New Genetic Markers That Shed Light on Psoriasis

OWCP and mediq Collaborate to Introduce Cannabinoid-based Psoriasis Cream in Germany

FDA Approves BLA Filing for Sun Pharma’s Lead Candidate Therapy Tildrakizumab to Treat Plaque Psoriasis

Janssen’s Phase 3 Trials for Guselkumab to Focus on Plaque Psoriasis, Psoriatic Arthritis

Remicade Can Be Substituted for Less Expensive Biosimilar CT-P13, Clinical Trial Suggests

Cannabinoids Have Potential to Treat Skin Conditions Like Psoriasis, Review Shows

Phase 2b Trial of Psoriasis Therapy Prurisol Reaches 70% of Participant Target

Pfizer’s Xeljanz Reduced Nail Psoriasis in Phase 3 Trials of Plaque Disease

FDA Accepts Pfizer’s Supplemental New Drug Application for Xeljanz to Treat Active Psoriatic Arthritis Patients

Cimzia and Cosentyx Approved to Treat Active Psoriatic Arthritis in England and Wales

Valeant Prices Plaque Psoriasis Treatment, Siliq, at $3,500 a Month

XTRAC Light Therapy Effectively Treats Psoriasis Lesions Without the Serious Side Effects of Rival Therapies, Says Strata